Effects of ligand activation of PPAR-gamma in human prostate cancer – (10-26-00)



Effects of ligand activation of PPAR-gamma in human prostate cancer

I’ve said many times before that I truly believe that most chronic diseases in humans stems from relatively few biochemical defects. This is yet more evidence of this. The new class of diabetic drugs have been shown to inhibit prostate cancer. Just remember that conjugated linoleic acid (CLA) is also a PPAR-gamma ligand without the known hepatotoxicity.

PNAS — Abstracts: Mueller et al. 97 (20): 10990

Read entire article here

James Bogash

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email:



Posted on
Category: Prostate Cancer
Disclosure of Material Connection: Some of the links in the post above are “affiliate links.” This means if you click on the link and purchase the item, I will receive an affiliate commission. Regardless, I only recommend products or services I use personally and believe will add value to my readers. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: “Guides Concerning the Use of Endorsements and Testimonials in Advertising.”